Triple-negative breast cancer trials recruiting in Indiana
All Triple-negative breast cancer trials nationally
9
Recruiting in Indiana
6
Cities with sites
Cities in Indiana
Indianapolis 7Fort Wayne 3Carmel 1Dyer 1Lafayette 1Munster 1
Recruiting trials in Indiana
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of LY4175408 in Participants With Advanced Cancer
- A Study of Tetrathiomolybdate (TM) Plus Capecitabine
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers